Latest Content

Experts share critical clinical protocols for managing daraxonrasib (Rasonque) following its landmark FDA approval.

Study of breast cancer survivors shows that depression and stress, rather than cardiac function decline, are the primary drivers of long-term fatigue.

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in patients with polycythemia vera.

New ASCO living guideline establishes standard-of-care frameworks for recurrent ovarian cancer, highlighting biomarkers and treatment sequencing.

Oncology nurses share high-level strategies for advanced RCC therapy, focusing on managing hypertension, diarrhea, and fatigue in the frontline.

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly three decades.

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple myeloma.

Sarah Cannon's Kelsey Martin, APRN, AOCNP, discusses managing toxicities, nursing collaboration, and tailored treatment sequencing in frontline mTNBC.

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, boosting outcomes.

Topline Phase 3 results show individualized mRNA therapy intismeran plus Keytruda significantly improves recurrence-free survival in melanoma.

Alanna Iorio, APRN-C, OCN, discusses managing toxicities, educating patients, and professional growth in triple-negative breast cancer care

The FDA has approved daraxonrasib for metastatic pancreatic cancer. MSK's Mary Larsen, MSN, RN, OCN, shares essential nursing protocols for care.

At the 29th APAO Symposium, Jennifer Fisher, PA-C, discussed combining surgery, radiation, and novel systemic drugs to treat brain metastases.